SEC Tracker
Get the app

Anaptysbio ANAB

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively

Form
8-K
Filed
Importance
Routine
  • Signs a material agreement (1.01)
  • Completes an acquisition or sale of assets (2.01)
  • Reports an executive or board change (5.02)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Anaptysbio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
  2. Stoke Therapeutics STOK public float $592M, Jun 30, 2025
  3. Trevi Therapeutics TRVI public float $588M, Jun 30, 2025
  4. ImmunityBio IBRX public float $690M, Jun 30, 2025
  5. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.